Spruce Biosciences, Inc. announced completion of enrollment in its CAHmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH). CAHmelia-204 is a randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of tildacerfont, a potentially novel, once-daily, non-steroidal treatment option, in reducing glucocorticoid usage in 100 adults with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of androstenedione (A4) at baseline. The primary endpoint of this clinical trial is the absolute change in daily glucocorticoid dose in hydrocortisone equivalents (HCe) from baseline at week 24.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.708 USD | -0.28% | +0.97% | -75.84% |
Mar. 15 | North American Morning Briefing : Inflation -2- | DJ |
Mar. 14 | Top Midday Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-75.84% | 29.14M | |
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |
- Stock Market
- Equities
- SPRB Stock
- News Spruce Biosciences, Inc.
- Spruce Biosciences, Inc. Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia